Jendle, J., Nauck, M., Matthews, D., Frid, A., Hermansen, K., During, M., Zdravkovic, M., Strauss, B., & Garber, A. (2016). The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat. DIABETOLOGIA, 51, S318–S318.

Jendle, J., et al. “The Reduction of Body Weight with Liraglutide, a Once-Daily Human GLP-I Analogue for Type 2 Diabetes, Primarily Comes from Fat Tissue and the Fat Tissue Lost Is Predominantly Visceral Fat.” DIABETOLOGIA, vol. 51, 2016, pp. S318–S318.

Jendle, J, M Nauck, D Matthews, A Frid, K Hermansen, M During, M Zdravkovic, B Strauss, and A Garber. 2016. “The Reduction of Body Weight with Liraglutide, a Once-Daily Human GLP-I Analogue for Type 2 Diabetes, Primarily Comes from Fat Tissue and the Fat Tissue Lost Is Predominantly Visceral Fat.” DIABETOLOGIA 51: S318–S318.